4 April 2023
Panel Discussion – Developing a Robust Global GMP Regulatory Strategy for Live Biotherapeutic Product Manufacturing
Access the Presentation Slides Here
2 March 2023
Biose Industrie announces the opening of new manufacturing development facility in Boston, MA
Aurillac, France, March 2nd, 2023 Biose Industrie, a contract development manufacturing organisation (CDMO) and a world-leader of live biotherapeutic product (LBP) process development and production, announced today their plan […]
17 February 2023
Biose Industrie to receive €80M in investment to boost workforce and manufacturing capabilities
L-GAM and the French State through the “French Tech Souveraineté” scheme have signed a purchase agreement with the aim of acquiring joint control of Biose Industrie, a world leader in […]
6 December 2022
Conference Highlights: Microbiome Connect USA
Introduction Kisaco Research’s flagship Microbiome Connect event returned to Boston in November. Joined by a range of microbiome companies and researchers, the event covered both the R&D and manufacturing considerations […]
23 November 2022
Targeting the Vaginal Microbiome to Develop Novel Therapeutics
The vaginal microbiota plays a key role in regulating vaginal health. Unlike other human microbiomes where bacterial diversity is positive, a healthy vaginal microbiota is associated with Lactobacillus species dominance. […]
22 September 2022
A roundup of research on the gut-kidney axis and new microbiome therapeutics
Within the body’s renal system, the kidneys are the main players. Each person’s kidneys manage to filter around 200 litres of fluid per day, working to remove toxins from the […]
4 August 2022
Conference Highlights: Microbiome Connect Europe
The Microbiome Connect Europe event, by Kisaco Research, was held recently in Amsterdam, the Netherlands. The speakers covered many facets of microbiome-focused products: discovery, clinical validation and mechanisms of action, […]
14 June 2022
Highlights of Pharmabiotics 2022: New therapeutics and regulatory directions
An in-person event, Pharmabiotics 2022, brought together individuals from academia and industry in the microbiome field to focus on how microbiome-based drug products will become a therapeutic reality in Europe. […]
28 April 2022
Understanding the gut-liver axis leads to microbiome-focused therapeutic options for liver diseases
Companies are now targeting the gut microbiome with therapies for fatty liver disease, hepatic encephalopathy, and more.. The liver is an incredibly complex organ—and its functioning leaves very little room […]